Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey
Most patients required to complete nonspecialty step therapy ultimately initiated specialty medications after a lengthy delay, demonstrating the potential impact of step therapy requirements on initiating clinically appropriate treatment for AD and PsO. Further research assessing the financial burden and clinical impact of requiring step therapy before specialty medications is warranted.
Authors
- Chelsea P. Renfro (ORCID: https://orcid.org/0000-0002-4090-8457)
- Autumn D. Zuckerman (ORCID: https://orcid.org/0000-0002-8376-0691)
- Leena Choi (ORCID: https://orcid.org/0000-0002-2544-7090)
- M. J. Bowles
- Josh DeClercq (ORCID: https://orcid.org/0000-0002-8171-5766)
- Melina Ellis (ORCID: https://orcid.org/0000-0002-8542-048X)
Institutions
- Lipscomb University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.18553/jmcp.2025.31.2.147
- Citations
- 1
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.47